Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others

Etsuko Tokunaga, Hidehiko Akiyama, Vadim A. Soloshonok, Yuki Inoue, Hideaki Hara, Norio Shibata

研究成果: Article査読

16 被引用数 (Scopus)


Over the last few years, thalidomide has become one of the most important anti-tumour drugs for the treatment of relapsed-refractory multiple myeloma. However, besides its undesirable teratogenic side effect, its configurational instability critically limits any further therapeutic improvements of this drug. In 1999, we developed fluoro-thalidomide which is a bioisostere of thalidomide, but, in sharp contrast to the latter, it is configurationally stable and readily available in both enantiomeric forms. The biological activity of fluoro-thalidomide however, still remains virtually unstudied, with the exception that fluoro-thalidomide is not teratogenic. Herein, we report the first biological evaluation of fluoro-thalidomide in racemic and in both (R)- and (S)-enantiomerically pure forms against (in vitro) H929 cells of multiple myeloma (MM) using an annexin V assay. We demonstrate that all fluoro-thalidomides inhibited the growth of H929 MM cells without any in-vivo activation. Furthermore, we report that the enantiomeric forms of fluoro-thalidomide display different anti-tumour activities, with the (S)-enantiomer being noticeably more potent. The angiogenesis of fluoro-thalidomides is also investigated and compared to thalidomide. The data obtained in this study paves the way towards novel pharmaceutical research on fluoro-thalidomides.

ジャーナルPloS one
出版ステータスPublished - 08-2017

All Science Journal Classification (ASJC) codes

  • 生化学、遺伝学、分子生物学(全般)
  • 農業および生物科学(全般)
  • 一般


「Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。